PFE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Pfizer Inc (PFE) is not a strong buy for a beginner investor with a long-term focus at this time. The stock faces significant headwinds, including declining revenue, negative net income, and upcoming patent expirations. While the company offers an attractive dividend yield of 6.3%, the lack of strong growth catalysts and neutral trading sentiment make it less appealing for immediate investment.
The stock shows a bullish trend with SMA_5 > SMA_20 > SMA_200, and the MACD histogram is positive at 0.134. RSI is neutral at 63.111. Key resistance levels are at R1: 27.731 and R2: 28.364, while support levels are at S1: 25.684 and S2: 25.051. However, the pre-market price is slightly down by -0.04%, indicating limited momentum.
Pfizer maintains a high dividend yield of 6.3%, which is attractive for income-focused investors. The company is advancing 20 pivotal clinical trials and has a promising obesity drug in clinical trials with results expected in June.
Revenue and net income have significantly declined in the latest quarter, with net income dropping by -501.95% YoY. The company faces a patent cliff in 2027-2028, creating uncertainty about future revenues. Analysts have downgraded the stock or maintained neutral ratings, reflecting cautious sentiment.
In Q4 2025, revenue dropped to $17.56 billion (-1.16% YoY), net income fell to -$1.65 billion (-501.95% YoY), and EPS declined to -$0.29 (-514.29% YoY). Gross margin increased to 64.15%, up 6.00% YoY, but overall financial performance remains weak.
Analysts are generally neutral on Pfizer, with recent price targets ranging from $25 to $35. The consensus reflects concerns about revenue uncertainty, patent expirations, and limited near-term catalysts. Some analysts highlight potential growth from obesity drug trials and other pipeline developments, but these are longer-term prospects.
